Results 1 to 10 of about 11,675 (152)

Mechanisms of Primary Membranous Nephropathy [PDF]

Biomolecules, 2021
Membranous nephropathy (MN) is an autoimmune disease of the kidney glomerulus and one of the leading causes of nephrotic syndrome. The disease exhibits heterogenous outcomes with approximately 30% of cases progressing to end-stage renal disease.
Yan Gu, Hui Xu, Damu Tang
doaj   +5 more sources

Primary Membranous Nephropathy With Enhanced Staining of Exostosin 1/Exostosin 2 in the Glomeruli: A Report of 2 Cases

Kidney Medicine, 2021
Technological advances have allowed the discovery of 6 subtypes of membranous nephropathy based on target antigens: M-type phospholipase A2 receptor (PLA2R), thrombospondin type 1 domain-containing 7A (THSD7A), neural epidermal growth factor-like 1 ...
Takamasa Iwakura, Chiemi Ema, Taichi Sato, Shinsuke Isobe, Tomoyuki Fujikura, Naro Ohashi, Akihiko Kato, Hideo Yasuda   +7 more
doaj   +3 more sources

Establishing a differential diagnosis model between primary membranous nephropathy and non-primary membranous nephropathy by machine learning algorithms [PDF]

Renal Failure
Context Four algorithms with relatively balanced complexity and accuracy in deep learning classification algorithm were selected for differential diagnosis of primary membranous nephropathy (PMN).Objective This study explored the most suitable ...
Shangmei Cao, Shaozhe Yang, Bolin Chen, Xixia Chen, Xiuhong Fu, Shuifu Tang   +5 more
doaj   +4 more sources

Primary Membranous Nephropathy with Crescents

Indian Journal of Kidney Diseases, 2023
We present the case of a 46-year-old patient with a history of hypertension, renal biopsy-proven primary membranous nephropathy, and a unique progression. He initially presented with edema and hypertension.
Megana Sunder, Balagurunathan Raghavan, Saravanan Margabandhu   +2 more
doaj   +2 more sources

Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy. [PDF]

Kidney Int Rep
Povetacicept is an inhibitor of B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), 2 cytokines central to the pathogenesis of autoimmune glomerulonephritis. Both BAFF and APRIL promote B-cell and plasma cell survival and function.
Madan A, Yalavarthy R, Kim DK, Moon JY, Park I, Mandayam S, Cortazar F, Kim SG, Enstrom A, Thomas H, Li J, Peng SL, Chen YC, Sanders J, Egbuna O, Tumlin J, AIS-D03 RUBY-3 Study Group.   +16 more
europepmc   +4 more sources

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy

Frontiers in Immunology, 2022
Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-antibodies targeting podocyte antigens resulting in activation of complement and damage to the glomerular basement membrane.
Maxime Teisseyre, Maxime Teisseyre, Marion Cremoni, Marion Cremoni, Sonia Boyer-Suavet, Caroline Ruetsch, Daisy Graça, Daisy Graça, Vincent L. M. Esnault, Vincent L. M. Esnault, Vesna Brglez, Vesna Brglez, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +15 more
doaj   +3 more sources

Primary membranous nephropathy with concomitant IgA nephropathy

Saudi Journal of Kidney Diseases and Transplantation, 2019
Membranous nephropathy (MN), an autoimmune glomerulonephritis which can occur in primary and secondary forms, is one of the most common inflammatory glomerulopathies in elderly patients.
Reza Khorsan, Ramy M Hanna, Khalid Ameen, Farid Arman, Niloofar Nobakht, Huma Hasnain, Ashley Hyunh, Anjay Rastogi   +7 more
doaj   +3 more sources

PLA2R1 and HLA-DQA1 SNP in patients with primary membranous nephropathy. [PDF]

PLoS ONE
BackgroundPrimary membranous nephropathy is a widely recognized autoimmune disease associated with podocyte antigens; the most important autoantigen is PLA2R1. PLA2R1 and HLA-DQA1 play important roles in the production of pathogenic antibodies.
Junyi Zhou, Zhijian Zhang, Kezhi Zhou, Leting Zhou, Jing Xue, Bin Liu, Xiran Zhang, Ting Cai, Biao Huang, Yi Zhang, Zhigang Hu, Liang Wang, Xiaobin Liu   +12 more
doaj   +2 more sources

Pharmacological treatment of primary membranous nephropathy in 2016 [PDF]

Expert Review of Clinical Pharmacology, 2016
Therapy in patients with primary membranous nephropathy is debated. The discovery of anti-PLA2R antibodies provides opportunities for new treatment strategies. Areas covered: The PubMed database and Cochrane library were searched for full-text articles published in English before March 2016.
Anne-Els Van De Logt, Julia M Hofstra, Jack F M Wetzels   +2 more
exaly   +3 more sources

Comparative efficacy and safety of rituximab versus cyclophosphamide with steroids in primary membranous nephropathy: a systematic review and meta-analysis [PDF]

BMC Nephrology
Background Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults. In some patients, PMN can be severe or continue to worsen even after 6 months of supportive treatment.
Fangjiao Huang, Chenxin Fu, Maorong Liu, Peiyu Wu, Yanfang Li, Zhuguang Lu, Yanlei Li, Yifeng Xie   +7 more
doaj   +2 more sources